Psoriasis is a chronic skin disease which to date, available treatments can only prevent symptoms remission. Plaque psoriasis is the most common type. Moderate to severe plaque psoriasis are commonly treated with systemic agents which bring systemic side effects that are unfavourable to patients. Researchers and clinicians are now looking at a novel highly selective TYK2 inhibitor agent, Deucravacitinib, which carries a lot less systemic side effects. We aim to review its efficacy on current studies available. We performed systematic review conducted from MEDLINE, ScienceDirect, and ProQuest library. The authors screened the articles based on inclusion criteria: (1) Trials including patients with moderate-to-severe plaque psoriasis for more than six months (2) Deucravacitinib as interventional therapy (3) Human studies that have PASI score as an outcome (4) Written in English. PASI, sPGA, and DLQI score improvements are outcomes measured in this review. Three randomized control trials (RCT) studies involving 1,943 patients were included. PASI75, PASI90, sPGA 0/1, and DLQI 0/1 achievements in all studies were significantly higher in subjects receiving Deucravacitinib compared to placebo and Apremilast—other active comparator. Deucravacitinib has been proven to be more efficacious in treating moderate to severe plaque psoriasis, even compared to another active biologic agent, Apremilast.

Psoriasis vulgaris

Plaque psoriasis

Deucravacitinib

Apremilast

Psoriasis Area and Severity Index

static Physician's Global Assessment

Dermatology Life Quality Index